Method for tumor treatment using infusion of xenogeneic cells to induce hyperacute rejection and innocent bystander effect
AssigneeHuman Gene Therapy Research Institute
InventorsCharles J. Link, Jr., Tatiana Seregina
Life of this patent
Estimating the term…
Abstract
A method for treating tumors. Through infusion or xenotransplantation of xenogeneic cells, such as infusion of murine cells into the peritoneal cavity of humans, a hyperacute rejection response to the cells is induced. This in turn creates a bystander effect to the tumor. This effect creates tumor regression. This treatment can be used alone or in conjunction with gene therapy or chemotherapy treatments.
Claims8
A method for treating a solid tumor in a human subject, the method comprising:
- administering to the subject and at or near the solid tumor an effective amount of xenogeneic retroviral vector producer cells having α(1,3)galactosyl epitopes to activate a hyperacute rejection response, wherein administration of said vector producer cells is not followed by treatment with ganciclovir.
A method for treating a solid tumor in the peritoneal cavity of a human subject having pre-existing anti-αGal antibodies, the method comprising:
- administering to the subject and at or near the solid tumor an effective amount of murine retroviral vector producer cells having α(1,3)galactosyl epitopes, wherein said amount activates a hyperacute rejection response against said xenogeneic cells and an innocent bystander immune response against tumor cells, thereby inhibiting the growth of a tumor in the subject wherein administration of said vector producer cells is not followed by treatment with ganciclovir.
A method for inhibiting the growth of a solid tumor in a human subject having pre-existing anti-αGal antibodies, the method comprising:
- delivering into or near the solid tumor an effective amount of a murine retroviral vector producer cells that expresses α(1,3)galactosyl epitopes thereby causing a local hyperacute rejection response against said xenogeneic cells and a bystander immune reaction against the tumor in the absence of ganciclovir thereby inhibiting the growth of the tumor in the subject, wherein administration of said vector producer cells is not followed by treatment with ganciclovir.
Dependencies are inferred from the claim text.